Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Styperek

Clinical Cardiac Electrophysiology Rome, GA Medical Doctor

NPI 1225193303 CMS profile 191360

19 John Maddox Dr Nw Ste B, Rome, GA 30165

Open in the dashboard

General payments

$28,850

332 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$143,414 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Robert Styperek of Rome, GA is reported in the CMS Open Payments database as having received $28,850 across 332 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $143,414 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 61st percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,970 56
2024 General $1,574 67
2023 General $1,152 41
2022 General $2,088 50
2021 General $1,281 26
2020 General $4,731 29
2019 General $16,054 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Styperek
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Robert Styperek were reported at $1,970. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Robert Styperek Clinical Cardiac Electrophysiology median Middle half National median
2019 $16,054 $2,361 $585–$8,260 $163
2020 $4,731 $993 $247–$4,351 $114
2021 $1,281 $1,185 $326–$4,739 $132
2022 $2,088 $2,073 $554–$6,789 $149
2023 $1,152 $2,568 $759–$8,159 $160
2024 $1,574 $2,557 $703–$7,403 $164
2025 $1,970 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Pharmaceuticals, Inc $11,863 26 payments
  2. E.R. Squibb & Sons, L.L.C. $7,239 14 payments
  3. Abbott Laboratories $4,539 91 payments
  4. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,317 51 payments
  5. Boston Scientific Corporation $1,110 29 payments
  6. Pfizer Inc. $708 44 payments
  7. Novartis Pharmaceuticals Corporation $644 34 payments
  8. Medtronic Vascular, Inc. $286 10 payments
  9. Medtronic, Inc. $247 5 payments
  10. Atricure, Inc. $200 3 payments
  11. Other $697 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $16,800 7 payments
  2. Food and Beverage $10,565 318 payments
  3. Travel and Lodging $1,485 7 payments
Products named General payments · program years 2019–2025
  1. XARELTO $11,863 26 payments
  2. ELIQUIS Cardiovascular $7,203 12 payments
  3. LifeVest $1,317 51 payments
  4. AVEIR Structural Heart $837 10 payments
  5. ACCENT $556 14 payments
  6. LEQVIO $539 27 payments
  7. ELIQUIS Cardiovascular;Metabolic Disease $477 36 payments
  8. Accent Pacemaker $426 6 payments
  9. WATCHMAN FLX $335 9 payments
  10. AVEIR Cardiac Rhythm Management $296 15 payments
  11. Other $5,667 172 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

5,729

Median for Cardiology: 2,533

Drug cost

$2,433,795

Median for Cardiology: $485,213

Branded share of claims

44.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 1,763 $1,830,570
Xarelto Rivaroxaban Brand 372 $419,906
Entresto Sacubitril/Valsartan Brand 63 $99,155
Flecainide Acetate Generic 504 $21,144
Farxiga Dapagliflozin Propanediol Brand 22 $17,257
Metoprolol Tartrate Generic 1,092 $6,774
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 20 $5,704
Sotalol Sotalol Hcl Brand 211 $4,830
Amiodarone Hcl Generic 243 $4,421
Diltiazem Hcl Generic 141 $4,412

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$362,729

Medicare's payments for the services billed

Medicare patients

1,533

Average age 77

Services billed

5,045

705 women, 828 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 74%
Heart failure 65%
Ischemic heart disease 59%
Arthritis 52%
Chronic kidney disease 45%
Diabetes 43%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $170
$170 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $127
$127 63 —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $32
  • PFIZER INC. $29
$61 1,763 —
XARELTO
  • Janssen Pharmaceuticals, Inc $31
$31 372 —
NURTEC ODT
  • PFIZER INC. $29
$29 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

332 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record